Show simple item record

HER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!

dc.contributor.authorGarg, Nen_US
dc.contributor.authorThorat, MAen_US
dc.date.accessioned2023-02-16T14:10:41Z
dc.date.available2023-01-15en_US
dc.date.issued2023en_US
dc.identifier.issn2331-4737en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/84482
dc.format.extent1 - 3en_US
dc.languageengen_US
dc.relation.ispartofOncoscienceen_US
dc.subjectDCISen_US
dc.subjectHER2en_US
dc.subjectpredictive biomarkeren_US
dc.subjectprognostic biomarkeren_US
dc.subjectradiotherapyen_US
dc.titleHER2 expression should be routinely evaluated in DCIS to avoid under or overtreatment!en_US
dc.typeArticle
dc.identifier.doi10.18632/oncoscience.572en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36733476en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume10en_US
dcterms.dateAccepted2023-01-15en_US
qmul.funderRecurrence in DCIS: A study of clinico-pathological and molecular variables to identify prognostic and predictive factors::Cancer Research UKen_US


Files in this item

Thumbnail
Name:
HER2 expression should be routinely ...
Size:
303.2Kb
Format:
application/
Description:
Published version
View/Open

This item appears in the following Collection(s)

Show simple item record